AR and prostate carcinoma: SSRs play a pivotal role in the development and progression of malignancies, such as prostate cancer [androgen receptor (AR; Heinlein and Chang, 2004), and breast cancer (estrogen receptor (ER)/progesterone receptor (PR; Brisken, 2013; Turner et al., 2017].